Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced data from the 24-week open-label extension of its 12-week, randomized, double-blind, placebo-controlled Phase IIb clinical trial of MIN-101 as monotherapy in patients with negative symptoms of schizophrenia. Data from the 12-week core phase of this trial were reported in May of this year.
Graphic representations of the data summarized below are available at
“Data from the extension phase demonstrate a further and continuous improvement in negative symptoms in patients with schizophrenia, as measured by the negative symptom subscales of the Positive and Negative Syndrome Scale (PANSS),” said Dr. Remy Luthringer, president and chief executive officer of Minerva. “The longer patients were on monotherapy with MIN-101, the greater improvement they were observed to experience in their negative symptoms during the entire extension period, without evidence of reaching a plateau. We believe that such continuous improvement in symptoms over a nine month period in this patient population is unprecedented.
Never heard of this drug until now. Do you think they will have an injection form, because my doctor doesn’t trust me taking oral pills. They think I won’t take them.
@Daze Seems intent on spoiling another thread. I think she’s never happy unless she’s in an argumentative frame of mind.
I would hope most consider this encouraging news.
Good news. It’s interesting that negative symptoms continued to improve over the course of the 9 months.
The longer patients were on monotherapy with MIN-101, the greater improvement they were observed to experience in their negative symptoms during the entire extension period, without evidence of reaching a plateau. We believe that such continuous improvement in symptoms over a nine month period in this patient population is unprecedented.
Yes @Chester170, phase 2 has ended earlier this year. Those who took part in phase 2 were able to keep taking Min-101 for another 6 months. This press release talks about results after those 6 months, and it is positive news. It seems negative symptoms keep improving: the longer one takes Min-101, the better they get.